The Quantellect read.As of Nov 19, 2026, 23 active firms cover Guardant Health Inc: 23 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $120.00 to $225.00, a moderate spread. The average target of $189.83 sits 31% above the current $145.09. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 22 to 23 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.28 next quarter toward $-0.28 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS23 active firms
Buy
Strong Buy00%
Buy23100%
Neutral00%
Sell00%
Strong Sell00%
Based on 23 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$189.83
+30.8% upside
Average target across 23 active firms as of Nov 19, 2026 vs $145.09 current
Highest Target$225.00
Average Target$189.83
Lowest Target$120.00
Detailed analyst forecasts for GH
Showing 1–23 of 23 named analysts shown · 23 active firms in the rating projection
As of Nov 19, 2026, 23 of 23 active firms rate GH a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
GH EPS & revenue forecast
EPS · NEXT QUARTER
$-0.28
Range $-0.52 – $-0.06 · 13 analysts · -37% YoY
Next period, 13 analysts expect Guardant Health Inc to earn $-0.28 a share (range $-0.52 – $-0.06), versus $-0.45 a year earlier. Full-year consensus is $-1.46, growing to $-0.28 the year after.
REVENUE · NEXT QUARTER
$394.3M
Range $380.7M – $410.9M · 13 analysts · +31% YoY
Revenue is expected to reach $394.3M (range $380.7M – $410.9M), +30.7% year-over-year. Full-year consensus is $1.4B, rising to $1.8B next year.
Top analysts covering Guardant Health Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on GH.
#1
Puneet Souda
Leerink Partners · Rank #30
Buy
No targeton GH
Overall win rate
57%
+ Follow
#2
Anthony Petrone
Mizuho · Rank #121
Buy
$200.00+37.8% to target
Overall win rate
45%
+ Follow
#3
MC
Mason Carrico
Stephens & Co. · Rank #178
Buy
$195.00+34.4% to target
Overall win rate
40%
+ Follow
#4
SJ
Sung Ji Nam
Scotiabank · Rank #186
Buy
$60.00-58.6% to target
Overall win rate
47%
+ Follow
#5
KM
Kyle Mikson
Canaccord Genuity · Rank #202
Buy
$205.00+41.3% to target
Overall win rate
40%
+ Follow
GH stock forecast FAQ
What is GH's average 12-month price target?+
The 23 active firms with a live target average $189.83 for Guardant Health Inc over the next 12 months, ranging from a $225.00 high to a $120.00 low, as of Nov 19, 2026.
Is GH stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 23 active firms as of Nov 19, 2026, 23 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for GH?+
The Street-high target is $225.00 (UBS), and the Street-low is $120.00 (Baird). The average of all 23 active-firm targets is $189.83.
How many active Wall Street firms cover GH?+
23 active firms have a recognized rating on Guardant Health Inc as of Nov 19, 2026, and 23 active firms carry a live 12-month price target.
Who is the most accurate analyst covering GH?+
Among analysts who currently cover GH, Puneet Souda of Leerink Partners has the strongest overall Quantellect track record (Rank #30). Their current call is Buy.
What is Guardant Health Inc's projected EPS for next quarter?+
The consensus estimate is $-0.28 per share (range $-0.52 – $-0.06) across 13 analysts. Full-year EPS is projected at $-1.46, rising to $-0.28 the following year.
How much revenue is Guardant Health Inc expected to report next quarter?+
Consensus revenue is $394.3M (range $380.7M – $410.9M). Full-year revenue is projected at $1.4B, growing to $1.8B next year.
Have analysts been upgrading or downgrading GH lately?+
As of Nov 19, 2026, 23 of 23 active firms rate GH a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their GH calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.